NASDAQ, RIGL #FDA Feedback #Featured #Letter to Shareholders #Trending News Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback October 10, 2022 16:45 EST –Announces Workforce Reduction– SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has received guidance from the U.S. Food and Drug Administration (FDA)’s review of the Company’s re-analysis of data from the FORWARD Phase 3 trial of fostamatinib for the No Comments
KRBP, NASDAQ #Event #FDA Feedback #Featured Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy October 6, 2022 08:08 EST HOUSTON–(BUSINESS WIRE)–Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it received validating written feedback on October 4, 2022 from the FDA No Comments
EIGR, NASDAQ #FDA Feedback #Featured #Hepatitis #Letter to Shareholders Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback October 5, 2022 08:00 EST PALO ALTO, Calif., Oct. 5, 2022 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration (FDA), the company will not submit No Comments
AMEX, ANVS, Tickers #FDA Feedback #Featured #Phase 3 Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson’s Disease January 25, 2022 09:00 EST Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson’s Disease FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson’s Disease Berwyn, Pennsylvania–(Newsfile Corp. – January 25, 2022) – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug No Comments
Tactile Systems Technology, Inc. Announces Pricing of $32.5 Million Public Offering of Common Stock 02/23/2023
Columbia Banking System Set to Join S&P MidCap 400; Verra Mobility to Join S&P SmallCap 600 02/23/2023
Global Payments Inc. (GPN) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Global Payments Inc. 02/21/2023
